Ascendis Pharma (NASDAQ: ASND) Reported Thursday August 13 Q2 2026 Financial Results With Product Revenue of €315 Million (+105% Year-Over-Year), Anchored by YORVIPATH (Palopegteriparatide, a TransCon Parathyroid Hormone Peptide Analog for Chronic Hypoparathyroidism) at €252 Million on Consistent New Patient Demand in the US and Continued Ex-US Global Launch Expansion With Full Reimbursement, SKYTROFA (Lonapegsomatropin, a TransCon Growth Hormone Peptide) at €55 Million, and YUVIWEL (TransCon C-Type Natriuretic Peptide for Achondroplasia) at €8 Million With More Than 220 US Patient Enrollments Through July 31, 2026; The YUVIWEL Launch Positions Ascendis Directly Against BioMarin's Voxzogo (Vosoritide) in the Same Achondroplasia Pediatric Indication and Opens a New Front in the CNP Peptide Analog Commercial Category
Ascendis Pharma (NASDAQ: ASND) reported Thursday August 13, 2026 Q2 2026 financial results with product revenue of €315 million (+105% year-over-year). YORVIPATH (palopegteriparatide, a TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) delivered €252 million on consistent new patient demand in the US and continued ex-US global launch expansion with full reimbursement in additional markets. SKYTROFA (lonapegsomatropin, a TransCon growth hormone peptide for pediatric growth hormone deficiency) delivered €55 million. YUVIWEL (TransCon C-type natriuretic peptide for achondroplasia) delivered €8 million with more than 220 US patient enrollments through July 31, 2026. Total Q2 revenue reached €339 million (+100% YoY) including €24 million in collaboration and milestone income. The YUVIWEL launch positions Ascendis directly against BioMarin's Voxzogo (vosoritide) in the same achondroplasia pediatric indication, opening a new front in the CNP peptide analog commercial category. YORVIPATH's €252 million quarterly revenue trajectory suggests a $1+ billion annual run-rate for the peptide franchise by end of 2026, a notable rare-disease peptide launch magnitude. Ascendis's TransCon platform uses a transient linker chemistry to release parent drug over an extended half-life, allowing weekly dosing of peptides that natively have short in vivo lifespans.